At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
LHW090 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
In Brief
A Phase 2 clinical trial evaluating LHW090 and Placebo for Patients, Resistant Hypertension. Completed, enrolled 64 participants across 16 sites in 6 countries.
Detailed Summary
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients, Resistant Hypertension
CountriesDenmark, France, Germany, Netherlands, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartNov 2015
Primary CompletionAug 2017
TodayJul 2026
First PostedAug 4, 2015
Enrollment StartNov 4, 2015
Primary CompletionAug 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.9 years ago
Interventions
LHW090drug
Capsule - oral dose
Placebodrug
Capsule - oral dose